145 related articles for article (PubMed ID: 32435849)
1. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?
Vernuccio F; Cannella R; Gozzo C; Greco V; Midiri M; Furlan A; Tang A; Brancatelli G
Abdom Radiol (NY); 2020 Aug; 45(8):2409-2417. PubMed ID: 32435849
[TBL] [Abstract][Full Text] [Related]
2. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients.
Furlan A; Close ON; Borhani AA; Wu YH; Heller MT
Clin Radiol; 2017 Jan; 72(1):93.e1-93.e6. PubMed ID: 27633725
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
Stocker D; Hectors S; Bane O; Vietti-Violi N; Said D; Kennedy P; Cuevas J; Cunha GM; Sirlin CB; Fowler KJ; Lewis S; Taouli B
Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
[TBL] [Abstract][Full Text] [Related]
6. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
7. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
Davenport MS; Caoili EM; Kaza RK; Hussain HK
Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733
[TBL] [Abstract][Full Text] [Related]
8. Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI.
Taibbi A; Brancatelli G; Matranga D; Midiri M; Lagalla R; Bartolotta TV
Diagn Interv Radiol; 2019 Mar; 25(2):95-101. PubMed ID: 30860073
[TBL] [Abstract][Full Text] [Related]
9. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
10. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.
Pietryga JA; Burke LM; Marin D; Jaffe TA; Bashir MR
Radiology; 2014 May; 271(2):426-34. PubMed ID: 24475864
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
[TBL] [Abstract][Full Text] [Related]
12. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.
Davenport MS; Viglianti BL; Al-Hawary MM; Caoili EM; Kaza RK; Liu PS; Maturen KE; Chenevert TL; Hussain HK
Radiology; 2013 Feb; 266(2):452-61. PubMed ID: 23192781
[TBL] [Abstract][Full Text] [Related]
13. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
14. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.
Feuerlein S; Boll DT; Gupta RT; Ringe KI; Marin D; Merkle EM
AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026
[TBL] [Abstract][Full Text] [Related]
15. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine.
Tirkes T; Mehta P; Aisen AM; Lall C; Akisik F
J Comput Assist Tomogr; 2015; 39(4):479-82. PubMed ID: 25783800
[TBL] [Abstract][Full Text] [Related]
17. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution.
Well L; Rausch VH; Adam G; Henes FO; Bannas P
Rofo; 2017 Jul; 189(7):651-660. PubMed ID: 28445909
[No Abstract] [Full Text] [Related]
18. Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA.
Vernuccio F; Bruno A; Costanzo V; Bartolotta TV; Vieni S; Midiri M; Salvaggio G; Brancatelli G
Curr Probl Diagn Radiol; 2020; 49(6):398-403. PubMed ID: 31253462
[TBL] [Abstract][Full Text] [Related]
19. The value of contrast-enhanced portal vein imaging at the hepatobiliary phase obtained with gadobenate dimeglumine for predicting decompensation and transplant-free survival in chronic liver disease.
Cai S; Lin N; Yang Y; Ma W; Wang Y; Lin X; Wang X; Zhao X
Eur Radiol; 2023 May; 33(5):3425-3434. PubMed ID: 36897349
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study.
Zech CJ; Schwenke C; Endrikat J
Magn Reson Insights; 2019; 12():1178623X19827976. PubMed ID: 30799932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
